Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808959 | 1.00 | NR3C1 (0.61) | NR3C1KDM4EMAPTALOX15MAPK1 | |
| SCHEMBL809000 | 0.87 | NR3C1 (0.62) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL809001 | 0.87 | NR3C1 (0.62) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL808999 | 0.87 | NR3C1 (0.62) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL809261 | 0.84 | NR3C1 (0.63) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL809262 | 0.84 | NR3C1 (0.63) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL27700376 | 0.83 | NR3C1 (0.42) | NR3C1KDM4EMAPTALOX15MAPK1 | |
| SCHEMBL809123 | 0.76 | NR3C1 (1.00) | NR3C1KDM5AKDM4CKDM5B | |
| SCHEMBL809048 | 0.74 | NR3C1 (0.62) | NR3C1 | |
| SCHEMBL809049 | 0.74 | NR3C1 (0.62) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776119-B9 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| EP-1776119-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-7902224-B2 | Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | NR3C1, NR3C2, MC2R | NR3C1 1/4885KDM4E 997/4885MAPT 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.